原始出處紀錄
重大申請已送件
PMV Pharmaceuticals 計劃於 2027 年第一季提交 rezatapopt NDA
PMV 已完成 PYNNACLE 試驗第 2 期單藥治療部分中鉑類抗藥性／難治性卵巢癌患者的主要分析入組。公司現計劃於 2027 年第一季提交 rezatapopt 在此適應症的加速核准 NDA。
關鍵事實
- 申報時間
- 2026年8月14日 下午12:00
- 事件
- 申請已送件
- 方向
- 中性
- 來源
- SEC 8-K
- 可信度
- 有出處
來源摘錄
EX-99.1 2 pmvp-ex99_1.htm EX-99.1 EX-99.1 Exhibit 99.1 PMV Pharmaceuticals Reports Second Quarter 2026 Financial Results and Corporate Highlights • Enrollment of platinum-resistant/refractory ovarian cancer patients for the primary analysis in the Phase 2 monotherapy portion of the PYNNACLE clinical trial completed • Rezatapopt NDA submission for platinum-resistant/refractory ovarian cancer planned in first quarter of 2027 • Cash, cash equivalents, and marketable securities of $79.4 million as of June 30, 2026 providing expected cash runway through second quarter of 2027 PRINCETON, N.J., August 14, 2026 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (“PMV Pharma” or the “Company”; Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule t